×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Wenjun Ouyang

Executive Director 
Inflammation and Oncology Research

Dr. Wenjun Ouyang joined the Department of Inflammation and Oncology, Amgen, as an Executive Director in 2015. Dr. Ouyang has led a group of scientists to develop innovative treatments in the areas of autoimmune diseases and cancer immunotherapies. He has provided strategic vision and planning to integrate human genetics, single cell RNA sequencing (scRNAseq)-based disease profiling, antibody engineering and T cell biology to build pipelines in IBD, asthma, COPD, psoriasis, and cancer immunotherapy.  Currently, his own research interests are focused on immunology, cancer immunotherapy, single cell technologies and human genetics. Since he joined Amgen, he has co-authored 25 papers, including co-senior author papers in Nature and Cell.

Before joining Amgen, Dr. Ouyang was a staff scientist and group leader in the Department of Immunology at Genentech. His lab has advanced several novel therapies, including IL-22Fc, into clinical trials for autoimmune diseases. He also oversaw the development of numerus other therapeutic projects such as anti-PDL1and anti-Tigit from his group in both autoimmunity and cancer immunotherapy. Dr. Ouyang’s own research at Genentech was centered on T cell and cytokine biology in various autoimmune diseases. He has made major scientific contributions in the fields of Th17 cell, IL-22 biology, and mucosal immunity.

Featured Publications

Zhang L, Yu X, Zheng L… Shen Z*, Ouyang W*, Zhang Z*. (2018) Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. *Corresponding authors. Nature 564(7735):268-272. https://www.nature.com/articles/s41586-018-0694-x

Zheng C, Zheng L, Yoo JK … Ouyang W*, Peng J*, Zhang Z*. (2017) Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. *Corresponding authors. Cell. 169(7):1342-1356. https://www.sciencedirect.com/science/article/pii/S0092867417305962

Wang X, Ota N, Manzanillo P … Kolumam G*, Ouyang W*. (2014) Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 514(7521):237-4 https://www.nature.com/articles/nature13564

Noubade R, Wong K, Ota N, Rutz S … Ouyang W. (2014) NRROS negatively regulates the production of reactive oxygen species in phagocytes during host defense and autoimmunity. Nature. 509(7499):235-9. https://www.nature.com/articles/nature13152

Zheng Y, Valdez PA, Danilenko DM … Ouyang W. (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 14(3):282-9. https://www.nature.com/articles/nm1720

Education

Ph.D., Immunology, Washington University School of Medicine, St. Louis
B.S., Biology, Peking University